This activity provides a summary and analysis of key clinical and scientific data from clinical trials and basic & translational research in melanoma presented at the 2022 European Society of Medical Oncology (ESMO) meeting.
NIVO and RELA versus NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Response Outcomes from
Be part of the knowledge.™Implementing Data Into Practice: Late-Breaking Melanoma Highlights From the 2022 European Oncology Meeting
NIVO and RELA versus NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Response Outcomes from RELATIVITY-047
MinuteCE®
Choose a format
Take 1 Minute Challenge
1 Minute Challenge Completed
Details
Presenters
Documents
Comments
Overview
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, including Medical Oncologists, Surgical Oncologists, Advanced Practice Nurses, Pharmacists, and other members involved in the management of patients with melanoma.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Evaluate recent practice-changing data to inform treatment strategies for patients with melanoma
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Provider(s)/Educational Partner(s)
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty have reported relationships with ineligible companies:
Dirk Schadendorf, MD, faculty for this educational event, receives research support from Amgen, Array/Pfizer, BMS, MSD, Novartis, and Roche; and receives consulting fees from 4SC, Amgen, Array Biopharma, AstraZeneca, BMS, Daiichi Sankyo, Haystack, Immunocore, InFlarX, Innovent, Labcorp, Merck Serono, MSD, Nektar, Neracare, Novartis, OncoSec, Pfizer, Philogen, Pierre Fabre, Replimune, Roche, Sandoz, Sanofi/Regeneron, and Sun Pharma.Sapna Patel, MD, faculty for this educational event, receives research support from Bristol Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, and TriSalus Life Sciences; and receives consulting fees from Advance Knowledge in Healthcare, Bristol Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Immunocore, Novartis, and TriSalus Life Sciences.
Paolo A. Ascierto, MD, faculty for this educational event, receives research support from Bristol Myers Squibb, Roche-Genentech, Array/Pfizer, and Sanofi; and receives consulting fees from Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, and Replimmune.
Jason Luke, MD, faculty for this educational event, receives research support from AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, and Xencor; receives consulting fees from Abbvie, Immutep, Evaxion, Alnylam, Atomwise, Bayer, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Kadmon, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Ribon, Roivant, Servier, STINGthera, Synlogic, Synthekine, 7 Hills, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio, Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, Pyxis, Saros, Stipe, and Tempest?; and has patent holdings for Serial #15/612,657 (Cancer Immunotherapy) and PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).
Zeynep Eroglu, MD, faculty for this educational event, receives research support from Pfizer and Novartis; and receives consulting fees for Regeneron, Genentech, Pfizer, Eisai, and OncoSec.
Planners and Managers Disclosure List
The following planners/reviewers/managers have reported no relationships with ineligible companies:
Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.
All the relevant financial relationships for these individuals have been mitigated.Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.Acknowledgment
This activity is supported by independent educational grants from Bristol Myers Squibb and Merck Sharp & Dohme LLC.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Fee Statement
This activity is FREE to all participants.
Instructions
During the period 9/30/2022 through 9/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date:
Expiration Date:
Presenters
Documents
Adjuvant Nivolumab Alone or in Combination with Ipilimumab Versus Placebo in Stage IV Melanoma with No Evidence of Disease: Overall Survival Results of IMMUNED, a Randomized, Double-Blind Multi-Center Phase 2p DeCOG Trial.pptx
Neoadjvuant Versus Adjuvant Pembrolizumab for Resected Stage III-IV Melanoma (SWOG S1801).pptx
Phase II Study SECOMBIT (Sequential Combo Immuno and Target Therapy Study): 4-Years OS Data and Preliminary Biomarkers Evaluation.pptx
Pembrolizumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma: Long-Term Quality of Life Analysis Results of the EORTC 1325-MG/Keynote-054 Double-Blinded Phase 3 Trial.pptx
NIVO and RELA versus NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Response Outcomes from RELATIVITY-047.pptx
Recent Advances in Melanoma from the 2022 European Congress.pptx
Facebook Comments